Karyopharm regains Nasdaq minimum bid price compliance

Karyopharm Therapeutics Inc.

Nasdaq confirmed Karyopharm regained compliance with Bid Price Rule on Feb 16, 2024.
Company met $1.00 minimum closing bid for 10 consecutive business days through Feb 15, 2024.
Non-compliance was first disclosed on Dec 12, 2023; this resolves the listing deficiency.
No effect on business operations or financial condition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.